Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis

Svatek, 2014, The economics of bladder cancer: costs and considerations of caring for this disease, Eur. Urol., 66, 253, 10.1016/j.eururo.2014.01.006 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur. Urol., 49, 466, 10.1016/j.eururo.2005.12.031 Matulay, 2020, Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG), BJU Int., 125, 497, 10.1111/bju.14995 Chang, 2016, Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline, J. Urol., 196, 1021, 10.1016/j.juro.2016.06.049 Babjuk M., Burger M., Compérat E., et al. European association of urology guidelines on non-muscle-invasive Bladder Cancer, 2020. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/. Accessed May 2020. Soloway, 2003, Expectant management of small, recurrent, noninvasive papillary bladder tumors, J. Urol., 70, 438, 10.1097/01.ju.0000076621.71247.6c Dekalo, 2018, Can urologists accurately stage and grade urothelial bladder cancer by assessing endoscopic photographs?, J. Telemed. Telecare, 24, 603, 10.1177/1357633X17727773 Herr, 2002, Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder, J. Urol., 168, 978, 10.1016/S0022-5347(05)64555-7 Mariappan, 2017, Predicting grade and stage at cystoscopy in newly presenting bladder cancers-a prospective double-blind clinical study, Urology, 109, 134, 10.1016/j.urology.2017.08.007 Martinez Caceres, 2005, Is it necessary to always treat the relapses of superficial bladder tumour at the moment of diagnosis? Preliminary communication, Actas. Urol. Esp., 29, 567 Pruthi, 2008, Conservative management of low risk superficial bladder tumors, J. Urol., 179, 87, 10.1016/j.juro.2007.08.171 Hernandez, 2009, Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma, Urology, 73, 1306, 10.1016/j.urology.2008.12.061 Hern"andez, 2016, Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer, Urol. Oncol., 34, 165.e19, 10.1016/j.urolonc.2015.11.005 Gofrit, 2006, Watchful waiting policy in recurrent Ta G1 bladder tumours, Eur. Urol., 49, 303, 10.1016/j.eururo.2005.12.029 ON, 2008, Active surveillance of low grade bladder tumors, Arch. Ital Urol. Androl., 80, 132 Parnasa, 2018, Active surveillance in recurrent low-risk bladder tumors, Harefuah, 157, 507 Lozano, 2014, Active surveillance in low risk bladder cancer. When TUR is recommended?, J. Urol., 191, e569, 10.1016/j.juro.2014.02.1582 Lozano, 2021, Active surviellance in low risk bladder cancer. Is it a safe option?, J. Urol., 201 Hurle, 2016, Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project, BJU Int., 118, 935, 10.1111/bju.13536 Hurle, 2018, Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project, J. Urol., 199, 401, 10.1016/j.juro.2017.08.091 Hurle, 2018, Pathological outcomes for patients who failed to remain under active surveillance for low-risk non-muscle-invasive bladder cancer: update and results from the Bladder Cancer Italian Active Surveillance project, Eur. Urol. Oncol., 1, 437, 10.1016/j.euo.2018.05.006 Hurle, 2019, Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project, World J. Urol., 5 Marcq, 2019, Active surveillance for non-muscle invasive bladder cancer, Transl. Androl. Urol., 8, 54, 10.21037/tau.2018.10.20 Hurle R., Maccagnano C. Active surveillance for recurrent low-grade non-muscle-invasive bladder cancer: can we take any advantage from the COVID-19 crisis? Arab. J. Urol. 2020. doi:10.1080/2090598X.2020.1772031.